KCK LTD.

In its 13F for Q4 2024 (holdings as of December 31, 2024, filed January 15, 2025), KCK LTD. reported 3 stock positions worth $75.0 million. Its top holding was Neuropace (NPCE) at 78.7% of the portfolio, followed by Sight Sciences (SGHT, 21.2%) and Rein Therapeutics (RNTX, 0.1%).

Most Recent 13F
Q3 2025
Location
HAMILTON, D0
CIK
0001657662
Portfolio Value
$75.0M (Q4 2024)
SEC Filing
0001012975-25-000044 ↗ filed Jan 15, 2025

Holdings Value

0$20.0M$40.0M$60.0M$80.0M Q4 2024: $75.0M $75.0M Q4 2024 Q1 2025: $10.5M Q1 2025 Q2 2025: $18.3M Q2 2025 Q3 2025: $15.1M Q3 2025

Holdings 3 stocks · $75.0M
NPCE Neuropace Inc. 78.69% 5,270,845 $59.0M —
SGHT Sight Sciences Inc. 21.25% 4,374,975 $15.9M —
RNTX Rein Therapeutics Inc. filed as AILERON THERAPEUTICS INC 0.07% 22,341 $51K —

Portfolio Sells Q4 2024

No earlier filing to compare with.

Portfolio Buys Q4 2024

No earlier filing to compare with.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2025 2$15.1MSGHT, RNTX
Q2 2025 2$18.3MSGHT, RNTX
Q1 2025 2$10.5MSGHT, RNTX
Q4 2024 3$75.0MNPCE, SGHT, RNTX